Vertex, FDA and Journavx

What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment
New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.
FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.
What Is Journavx, A New Non-opioid Pain Reliever Approved By FDA in Decades?
The US Food and Drug Administration has approved Journavx, also known as suzetrigine 50 milligram oral tablets—a first-in-class non-opioid analgesic—to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signalling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain.
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute
Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...